Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Aug;14(2):219–223. doi: 10.1111/j.1365-2125.1982.tb01965.x

Enhanced metabolism of mexiletine after phenytoin administration.

E J Begg, P M Chinwah, C Webb, R O Day, D N Wade
PMCID: PMC1427733  PMID: 7104173

Abstract

1 Unexpectedly low plasma concentrations of mexiletine were observed in three patients treated with mexiletine and concurrently taking phenytoin. 2 Six healthy volunteers were given a single oral dose of mexiletine (400 mg), before and after 1 week of phenytoin administration (300 mg/day). 3 The mean +/- s.d. area under the plasma mexiletine concentration-time curve decreased from 17.67 +/- 6.21 to 8.01 +/- 3.64 micrograms ml-1 h (P less than 0.003). 4 The mean +/- s.d. half-life of elimination of mexiletine decreased from 17.2 +/- 5.26 to 8.4 +/- 4.17 h (P less than 0.02) 5 The suggested mechanism of the interaction is hepatic mixed-function oxidase enzyme induction by phenytoin. 6 The interaction is likely to be clinically significant.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitio M. L., Mansury L., Tala E., Haataja M., Aitio A. The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol. 1981 Mar;11(3):279–285. doi: 10.1111/j.1365-2125.1981.tb00535.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beckett A. H., Chidomere E. C. The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J. 1977;53 (Suppl 1):60–68. [PubMed] [Google Scholar]
  3. Campbell N. P., Kelly J. G., Adgey A. A., Shanks R. G. Mexiletine in normal volunteers. Br J Clin Pharmacol. 1978 Oct;6(4):372–373. doi: 10.1111/j.1365-2125.1978.tb00868.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campbell N. P., Kelly J. G., Adgey A. A., Shanks R. G. The clinical pharmacology of mexiletine. Br J Clin Pharmacol. 1978 Aug;6(2):103–108. doi: 10.1111/j.1365-2125.1978.tb00833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Campbell N. P., Kelly J. G., Shanks R. G., Chaturvedi N. C., Strong J. E., Pantridge J. F. Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet. 1973 Aug 25;2(7826):404–407. doi: 10.1016/s0140-6736(73)92271-x. [DOI] [PubMed] [Google Scholar]
  6. Chew C. Y., Collett J., Singh B. N. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs. 1979 Mar;17(3):161–181. doi: 10.2165/00003495-197917030-00003. [DOI] [PubMed] [Google Scholar]
  7. Data J. L., Wilkinson G. R., Nies A. S. Interaction of quinidine with anticonvulsant drugs. N Engl J Med. 1976 Mar 25;294(13):699–702. doi: 10.1056/NEJM197603252941305. [DOI] [PubMed] [Google Scholar]
  8. Fine A., Henderson I. S., Morgan D. R., Tilstone W. J. Malabsorption of frusemide caused by phenytoin. Br Med J. 1977 Oct 22;2(6094):1061–1062. doi: 10.1136/bmj.2.6094.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnston A., Burgess C. D., Warrington S. J., Wadsworth J., Hamer N. A. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers. Br J Clin Pharmacol. 1979 Oct;8(4):349–352. doi: 10.1111/j.1365-2125.1979.tb04717.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaye C. M., Kiddie M. A., Turner P. Variable pharmacokinetics of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):56–59. [PubMed] [Google Scholar]
  11. Kelly J. G. Measurement of plasma mexiletine concentrations. Postgrad Med J. 1977;53 (Suppl 1):48–49. [PubMed] [Google Scholar]
  12. Perucca E., Richens A. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. Br J Clin Pharmacol. 1979 Jul;8(1):21–31. doi: 10.1111/j.1365-2125.1979.tb05904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Prescott L. F., Pottage A., Clements J. A. Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):50–55. [PubMed] [Google Scholar]
  14. Routledge P. A., Stargel W. W., Finn A. L., Barchowsky A., Shand D. G. Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol. 1981 Nov;12(5):663–666. doi: 10.1111/j.1365-2125.1981.tb01286.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Talbot R. G., Nimmo J., Julian D. G., Clark R. A., Neilson J. M., Prescott L. F. Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet. 1973 Aug 25;2(7826):399–404. doi: 10.1016/s0140-6736(73)92270-8. [DOI] [PubMed] [Google Scholar]
  16. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]
  17. Wing L. M., Meffin P. J., Grygiel J. J., Smith K. J., Birkett D. J. The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol. 1980 May;9(5):505–509. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES